Organogenesis Holdings Inc. (NASDAQ:ORGO) to Post FY2023 Earnings of $0.06 Per Share, Cantor Fitzgerald Forecasts

Organogenesis Holdings Inc. (NASDAQ:ORGOFree Report) – Analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for Organogenesis in a research report issued to clients and investors on Wednesday, February 7th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings of $0.06 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $5.00 target price on the stock. The consensus estimate for Organogenesis’ current full-year earnings is $0.05 per share. Cantor Fitzgerald also issued estimates for Organogenesis’ FY2024 earnings at $0.05 EPS.

Several other analysts have also commented on the company. BTIG Research boosted their price target on Organogenesis from $4.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, December 27th. Morgan Stanley boosted their price target on Organogenesis from $3.00 to $3.50 and gave the company an “equal weight” rating in a research note on Tuesday, November 14th.

Read Our Latest Stock Report on Organogenesis

Organogenesis Price Performance

Shares of ORGO stock opened at $3.65 on Friday. The stock’s fifty day simple moving average is $3.69 and its 200 day simple moving average is $3.07. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.77 and a quick ratio of 2.43. The firm has a market cap of $481.95 million, a price-to-earnings ratio of 36.50 and a beta of 1.59. Organogenesis has a one year low of $1.79 and a one year high of $4.70.

Organogenesis (NASDAQ:ORGOGet Free Report) last released its quarterly earnings data on Thursday, November 9th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01. The business had revenue of $108.53 million for the quarter, compared to analysts’ expectations of $112.75 million. Organogenesis had a return on equity of 4.83% and a net margin of 2.90%.

Insider Activity at Organogenesis

In other Organogenesis news, major shareholder Albert Erani sold 197,921 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $4.37, for a total value of $864,914.77. Following the transaction, the insider now owns 59,025,106 shares of the company’s stock, valued at $257,939,713.22. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 34.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Organogenesis

Large investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its stake in shares of Organogenesis by 80.1% during the first quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company’s stock valued at $41,000 after acquiring an additional 2,396 shares during the period. Point72 Hong Kong Ltd lifted its stake in shares of Organogenesis by 245.7% during the second quarter. Point72 Hong Kong Ltd now owns 6,015 shares of the company’s stock valued at $29,000 after acquiring an additional 4,275 shares during the period. Lazard Asset Management LLC lifted its stake in shares of Organogenesis by 3,808.2% during the first quarter. Lazard Asset Management LLC now owns 9,106 shares of the company’s stock valued at $69,000 after acquiring an additional 8,873 shares during the period. Principal Financial Group Inc. acquired a new position in shares of Organogenesis during the third quarter valued at $32,000. Finally, Great Lakes Advisors LLC acquired a new position in shares of Organogenesis during the second quarter valued at $35,000. Institutional investors and hedge funds own 39.48% of the company’s stock.

Organogenesis Company Profile

(Get Free Report)

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage.

See Also

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.